Emmanuel Ledoult1,2,3,4, Maxime Morelle5, Clio Baillet5,6, David Launay7,8,9, Michael Soussan10, Arsène Mékinian11,12, Hélène Béhal13, Vincent Sobanski7,8,9, Eric Hachulla7,8,9, Damien Huglo5,14, Noémie Le Gouellec8,15, Martine Remy-Jardin16. 1. Univ. Lille, INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France. emmanuel.ledoult@univ-lille.fr. 2. Univ. Lille, CHU Lille, Service de Médecine Interne, Centre de Référence des Maladies Auto-immunes et Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000, Lille, France. emmanuel.ledoult@univ-lille.fr. 3. Inserm, U1286, F-59000, Lille, France. emmanuel.ledoult@univ-lille.fr. 4. Hôpital Claude Huriez, Service de Médecine Interne, Rue Michel Polonovski, F59037, Lille Cedex, France. emmanuel.ledoult@univ-lille.fr. 5. CHU Lille, Service de Médecine Nucléaire, F-59000, Lille, France. 6. Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France. 7. Univ. Lille, INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France. 8. Univ. Lille, CHU Lille, Service de Médecine Interne, Centre de Référence des Maladies Auto-immunes et Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000, Lille, France. 9. Inserm, U1286, F-59000, Lille, France. 10. CH Avicenne - APHP, Service de Médecine Nucléaire, F-93000, Bobigny, France. 11. Hôpital Saint-Antoine - APHP, Service de Médecine Interne, F-75012, Paris, France. 12. Sorbonne Université, F-75571, Paris Cedex 12, France. 13. Univ. Lille, CHU Lille, ULR 2694 - METRICS : Évaluation des technologies de santé et des pratiques médicales, F-59000, Lille, France. 14. Univ. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000, Lille, France. 15. CH Valenciennes, Service de Médecine Interne, Centre de Compétences adultes pour les maladies auto-immunes et systémiques rares, F-59300, Valenciennes, France. 16. Univ. Lille, CHU Lille, Service d'imagerie Thoracique, F-59000, Lille, France.
Abstract
BACKGROUND: Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool in the managing of SSc-ILD. METHODS: In our center, SSc patients and controls (non-Hodgkin lymphoma cured after first-line regimen) who had received a PET/CT were screened retrospectively. The FDG uptake (visual intensity, pattern, SUVmax) was systematically recorded in > 30 regions of interest (ROIs) linked to SSc in a blind reviewing by 2 independent nuclear medicine physicians using a standardized form. RESULTS: Among the 545 SSc patients followed up in our center, 36, including 22 SSc-ILDs, had a PET/CT, whose indication was cancer screening in most cases. The mean ± SD age was 57.9 ± 13.0 years with 20/36 females. Fourteen patients had a disease duration of less than 2 years. A third had anti-centromere antibodies and 27.8% had anti-topoisomerase antibodies. Pulmonary FDG uptakes were higher in SSc patients than in controls (n = 89), especially in those with ILD compared with those without ILD. Pulmonary FDG uptakes were positively correlated with the ILD severity (fibrosis extent, %FVC, and %DLCO). No significant difference was found in the FDG uptakes from extrathoracic ROIs. Progressing SSc-ILDs within the 2 years after PET/CT (n = 9) had significant higher pulmonary FDG uptakes at baseline than stable SSc-ILDs (n = 13). CONCLUSION: PET/CT could be a useful tool in the assessment of the severity and the prediction of pulmonary function outcome of SSc-ILD.
BACKGROUND:Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool in the managing of SSc-ILD. METHODS: In our center, SSc patients and controls (non-Hodgkin lymphoma cured after first-line regimen) who had received a PET/CT were screened retrospectively. The FDG uptake (visual intensity, pattern, SUVmax) was systematically recorded in > 30 regions of interest (ROIs) linked to SSc in a blind reviewing by 2 independent nuclear medicine physicians using a standardized form. RESULTS: Among the 545 SSc patients followed up in our center, 36, including 22 SSc-ILDs, had a PET/CT, whose indication was cancer screening in most cases. The mean ± SD age was 57.9 ± 13.0 years with 20/36 females. Fourteen patients had a disease duration of less than 2 years. A third had anti-centromere antibodies and 27.8% had anti-topoisomerase antibodies. Pulmonary FDG uptakes were higher in SSc patients than in controls (n = 89), especially in those with ILD compared with those without ILD. Pulmonary FDG uptakes were positively correlated with the ILD severity (fibrosis extent, %FVC, and %DLCO). No significant difference was found in the FDG uptakes from extrathoracic ROIs. Progressing SSc-ILDs within the 2 years after PET/CT (n = 9) had significant higher pulmonary FDG uptakes at baseline than stable SSc-ILDs (n = 13). CONCLUSION:PET/CT could be a useful tool in the assessment of the severity and the prediction of pulmonary function outcome of SSc-ILD.
Authors: Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky Journal: N Engl J Med Date: 2006-06-22 Impact factor: 91.245
Authors: Thida Win; Tryphon Lambrou; Brian F Hutton; Irfan Kayani; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Pauline Lukey; Ashley M Groves Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-30 Impact factor: 9.236
Authors: Thida Win; Benjamin A Thomas; Tryphon Lambrou; Brian F Hutton; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Asim Afaq; Pauline Lukey; Peter J Ell; Ashley M Groves Journal: Eur J Nucl Med Mol Imaging Date: 2013-08-14 Impact factor: 9.236
Authors: Andréa L Bastos; Gilda A Ferreira; Marcelo Mamede; Eliane V Mancuzo; Mauro M Teixeira; Flávia P S T Santos; Cid S Ferreira; Ricardo A Correa Journal: J Bras Pneumol Date: 2022-06-06 Impact factor: 2.800
Authors: Bo Broens; Conny J van der Laken; Gerben J C Zwezerijnen; Esther J Nossent; Lilian J Meijboom; Julia Spierings; Jeska K de Vries-Bouwstra; Jacob M van Laar; Alexandre E Voskuyl Journal: Front Immunol Date: 2022-07-05 Impact factor: 8.786